ReviewMultiple sclerosis (Houndmills, Basingstoke, England)2014
Risk evaluation and monitoring in multiple sclerosis therapeutics.
Review in Multiple sclerosis (Houndmills, Basingstoke, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.Multiple sclerosis (Houndmills, Basingstoke, England) · 2018Trial
- An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion.Neurology and therapy · 2019Article
- Cladribine tablets' potential role as a key example of selective immune reconstitution therapy in multiple sclerosis.Degenerative neurological and neuromuscular disease · 2018Review
- Caught in a no-win situation: discussions about CCSVI between persons with multiple sclerosis and their neurologists - a qualitative study.BMC neurology · 2017Article
- The tension between early diagnosis and misdiagnosis of multiple sclerosis.Nature reviews. Neurology · 2017Review
- Regulatory T cells in multiple sclerosis and myasthenia gravis.Journal of neuroinflammation · 2017Review
- Halo and spillover effect illustrations for selected beneficial medical devices and drugs.BMC public health · 2016Article
- Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey.Therapeutic advances in neurological disorders · 2016Article
- Multiple sclerosis in men: management considerations.Journal of neurology · 2016Review
- Multiple sclerosis in 2015: Managing the complexity of multiple sclerosis.Nature reviews. Neurology · 2016Review
- Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016Review
- Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2015Review
- Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundRisk for multiple sclerosis (MS) disease-modifying therapies (DMT) must be assessed on an ongoing basis. Early concerns regarding the first-approved DMTs for MS have been mitigated, but recently licensed therapies have been linked to possibly greater risks.
objectivesThe objective of this review is to discuss risk assessment in MS therapeutics based on an international workshop and comprehensive literature search and recommend strategies for risk assessment/monitoring.
resultsAssessment and perception of therapeutic risks vary between patients, doctors and regulators. Acceptability of risk depends on the magnitude of risk and the demonstrated clinical benefits of any agent. Safety signals must be distinguishable from chance occurrences in a clinical trial and in long-term use of medications. Post-marketing research is crucial for assessing longer-term safety in large patient cohorts. Reporting of adverse events is becoming more proactive, allowing more rapid identification of risks. Communication about therapeutic risks and their relationship to clinical benefit must involve patients in shared decision making.
conclusionsIt is difficult to produce a general risk-assessment algorithm for all MS therapies. Specific algorithms are required for each DMT in every treated-patient population. New and evolving risks must be evaluated and communicated rapidly to allow patients and physicians to be well informed and able to share treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.